"Cytochrome P-450 CYP2D6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
| Descriptor ID |
D019389
|
| MeSH Number(s) |
D08.244.453.005.600 D08.244.453.491.372 D08.811.682.690.708.170.010.600 D08.811.682.690.708.170.450.368 D12.776.422.220.453.010.600 D12.776.422.220.453.491.368
|
| Concept/Terms |
Cytochrome P-450 CYP2D6- Cytochrome P-450 CYP2D6
- CYP2D6, Cytochrome P-450
- Cytochrome P 450 CYP2D6
- P-450 CYP2D6, Cytochrome
- Sparteine Monooxygenase
- Monooxygenase, Sparteine
- Cytochrome P450 2D6
- P450 2D6, Cytochrome
- Debrisoquine 4-Monooxygenase
- 4-Monooxygenase, Debrisoquine
- Debrisoquine 4 Monooxygenase
- Imipramine 2-Hydroxylase
- 2-Hydroxylase, Imipramine
- Imipramine 2 Hydroxylase
- CYP2D6
- CYP 2D6
- Debrisoquine 4-Hydroxylase
- 4-Hydroxylase, Debrisoquine
- Debrisoquine 4 Hydroxylase
- Debrisoquine Hydroxylase
- Hydroxylase, Debrisoquine
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6" by people in this website by year, and whether "Cytochrome P-450 CYP2D6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 4 | 1 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6" by people in Profiles.
-
The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice. Eur J Pharm Sci. 2023 Feb 01; 181:106358.
-
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clin Pharmacol Ther. 2023 03; 113(3):643-659.
-
Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genet Med. 2022 05; 24(5):1062-1072.
-
Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing? J Mol Diagn. 2022 03; 24(3):253-261.
-
Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021 02; 590(7845):290-299.
-
Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. Am J Geriatr Psychiatry. 2020 06; 28(6):609-629.
-
CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. J Clin Oncol. 2020 02 20; 38(6):558-566.
-
Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. Nat Commun. 2018 02 26; 9(1):828.
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
-
Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. Pharmacogenomics J. 2018 04; 18(2):201-208.